The Alphamab R&D team has successfully developed integrated technology platforms for biologics through a deep understanding of protein structure and function, combined with the bioinformatics analysis and prediction. These technology platforms include the proprietary glycan-specific conjugation platform, linker-payload platform, proprietary bispecific antibody platform, subcutaneous high concentration formulation platform and single-domain antibody platform.
The innovative technology platforms support a focus on multidimensional antibody modification technologies, enabling the independent development of a product pipeline with significant differentiated advantages, which constitutes the core competitive strength of Alphamab.
